ETA
19.5.2023 18:55:34 CEST | Business Wire | Press release
If you are planning a family holiday, look no further than Egypt. The country is renowned for its all-inclusive hotels and resorts that cater to the needs of families with children. These resorts offer entertainment programs and excursions suitable for all age groups. Museums and cultural sights also offer family-friendly activities. Furthermore, Egypt's warm temperatures and dry climate throughout the year make it an ideal destination for holidays all year round, with sandy beaches and shallow water that are sure to excite children.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230519005234/en/
Family Holiday in Egypt (Photo: Business Wire)
What Makes a Holiday Family-Friendly?
A holiday is meant to be a time for relaxation, escaping everyday life and enjoying oneself. However, this can be challenging when traveling with children. Egypt's all-inclusive hotels and resorts provide stress-free options for families with children. The resorts offer animation programs for children of different ages, with pools featuring water slides and children's pools. In addition, multilingual caretakers are available to look after children when parents want to pursue their own plans undisturbed for an afternoon or evening. This allows parents to relax and enjoy their holiday with peace of mind.
Activities for the whole Family
There are many activities that families can enjoy together in Egypt. Clubs and resorts offer a range of sports activities, including mini golf, beach football, and volleyball. For those interested in water activities like diving, snorkelling, or kite surfing, there are beginner courses as well as special children's courses available.
In the cities itself, families can find a variety of activities like water parks, amusement parks, safari tours, and aquariums. Additionally, museums can be a great way to make history exciting for children, with the Egyptian Museum in Cairo offering guided tours specifically designed for kids. Outside of the cities, families can have adventures like desert tours in buggies or riding on camels. Compared to similar activities in Europe, leisure activities in Egypt are much more affordable, allowing families to experience more together or take some time for themselves to relax.
"Nile Trips and Abu Simbel"
Aswan, the southernmost city in Egypt, is located directly on the Nile, making it an excellent starting point for interesting and varied tours. Visitors can take Nile trips to the temples of Kom Ombo and even further north to Luxor. Close to the city lies Lake Nasser, at the southern end of which stands the spectacular temple complex of Abu Simbel. The four 20-metre-high statues of Pharaoh Ramses II at the main entrance of the temple are an incomparable sight and rightly rank among the most popular sights in the country.
Aswan itself is also full of treasures to discover, such as the Agha Khan Mausoleum on the west bank of the Nile, or the archaeological Nubian Museum that highlights the history of the Nubian population, who make up a large part of Aswan's inhabitants. The city also includes numerous islands in the Nile, such as Elephantine Island, or Kitchener Island to the north, where the city's botanical garden can be found.
Background information on the Egyptian Tourism Authority
The Egyptian Tourism Authority (ETA) was established in 1981 to boost international tourism by highlighting Egypt's long history and traditional civilization and promoting the country and its many tourist attractions. ETA's mission also includes promoting domestic tourism, raising awareness of tourism throughout the country, and strengthening the connection between Egyptians and their heritage.
The ETA's focus is on the one hand on the diversity of attractions and destinations within Egypt, and on the other hand on developing marketing strategies and programs to promote tourism, as well as providing technical and marketing support. It also organizes and sponsors tourism, sports, and social and cultural events throughout the country. The ETA Board of Directors is chaired by the Minister of Tourism.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230519005234/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
